Quality of life in male breast cancer patients: psychosocial impacts and therapeutic strategies

Male breast cancer (MBC) is a rare malignant tumor that is infrequently diagnosed in men. This leads to a lower quality of life (QOL) in men adversely affecting their overall well-being. Therefore, we aimed to summarize and disseminate the evidence on the impact of breast cancer treatment on men’s QOL. Following scoping review guidelines, we conducted a scoping review by searching PubMed, Web of Science, Embase, Academic Search Ultimate, Medline and Google Scholar using keywords such as “breast cancer”, “male breast cancer”, “male breast cancer treatment” and “male breast cancer prevention”, combined with terms like “quality of life”, “complications”, “recurrence” and “metastasis”. Out of 308 results, 13 articles met our inclusion criteria after removing duplicates, irrelevant titles and non-English publications, focusing on studies published between 2010 and 2024. Evidence related to the impact of breast cancer on men’s QOL was grouped into three themes: (1) decreased survival due to metastases to other bodies after breast cancer treatment, (2) local recurrence of the tumor or development of complications, and (3) decreased QOL due to psychosocial problems in men after breast cancer treatment. Studies show that even after breast cancer treatment, men remain at risk for tumor metastasis and may experience anxiety overcomplications, local recurrence and psychosocial concerns about body image and life expectancy. In treatment of MBC, the development of new therapies and chemotherapy regimens that creduce the risk of metastasis, complications and local recurrence is crucial for improving the QOL of patients suffering from MBC.

Male breast cancer; Quality of life; Men’s health; Psychosocial problems; Treatment; Chemotherapy

[1] Konduri S, Singh M, Bobustuc G, Rovin R, Kassam A. Epidemiology of male breast cancer. The Breast. 2020; 54: 8–14.

[2] Hodgson NC, Button JH, Franceschi D, Moffat FL, Livingstone AS. Male breast cancer: is the incidence increasing? Annals of Surgical Oncology. 2004; 11: 751–755.

[3] Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Medical Oncology. 2021; 38: 39.

[4] Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiology, Biomarkers & Prevention. 2017; 26: 632–641.

[5] DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69: 438–451.

[6] Park S, Hur H, Lee JS, Yoon J, Hur SM, Chung IY, et al. Prognostic factors in male breast cancer: a retrospective nationwide study in south Korea by the study of SMARTSHIP Group. Journal of Breast Cancer. 2021; 24: 561–568.

[7] Mansoor NS, Arifin F, Kornain NKM, Razalli MM. A rare invasive male breast cancer of nonspecific type presenting at a primary care clinic: importance of early diagnosis and management. Journal of Family and Community Medicine. 2023; 30: 65–67.

[8] Wu SC, Chiang MC, Lee YG, Wang MW, Li CF, Tung TH, et al. Long-term survival and prognostic implications of patients with invasive breast cancer in southern Taiwan. Medicine. 2020; 99: e19122.

[9] Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K. Lymph node imaging in patients with primary breast cancer: concurrent diagnostic tools. The Oncologist. 2020; 25: e231–e242.

[10] Yadav S, Karam D, Bin Riaz I, Xie H, Durani U, Duma N, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 2020; 126: 26–36.

[11] Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program. Annals of Oncology. 2018; 29: 405–417.

[12] You CP, Tsoi H, Man EPS, Leung MH, Khoo US. Modulating the activity of androgen receptor for treating breast cancer. International Journal of Molecular Sciences. 2022; 23: 15342.

[13] Shin WS, Han SH, Jo KW, Cho Y, Kim KT. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer. Scientific Reports. 2023; 13: 16663.

[14] Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, et al. Prospective evaluation of risk factors for male breast cancer. Journal of the National Cancer Institute. 2008; 100: 1477–1481.

[15] Oh H, Wild RA, Manson JE, Bea JW, Shadyab AH, Pfeiffer RM, et al. Obesity, height, and serum androgen metabolism among postmenopausal women in the women’s health initiative observational study. Cancer Epidemiology, Biomarkers & Prevention. 2021; 30: 2018–2029.

[16] Al-Shami K, Awadi S, Khamees A, Alsheikh AM, Al-Sharif S, Ala’ Bereshy R, et al. Estrogens and the risk of breast cancer: a narrative review of literature. Heliyon. 2023; 9: e20224.

[17] Yalaza M, İnan A, Bozer M. Male breast cancer. European Journal of Breast Health. 2016; 12: 1–8.

[18] Abboah-Offei M, Bayuo J, Salifu Y, Afolabi O, Akudjedu TN. Experiences and perceptions of men following breast cancer diagnosis: a mixed method systematic review. BMC Cancer. 2024; 24: 179.

[19] Nguyen TS, Bauer M, Maass N, Kaduszkiewicz H. Living with male breast cancer: a qualitative study of men’s experiences and care needs. Breast Care. 2020; 15: 6–12.

[20] Eaton LH, Narkthong N, Hulett JM. Psychosocial issues associated with breast cancer-related lymphedema: a literature review. Current Breast Cancer Reports. 2020; 12: 216–224.

[21] Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005; 8: 19–32.

[22] Katano K, Yoshimitsu Y, Kyuno T, Haba Y, Maeda T, Kitamura S. Temporary spontaneous regression of male breast cancer: a case report. Surgical Case Reports. 2020; 6: 311.

[23] Cho O, Chun M, Kim SW, Jung YS, Yim H. Lymphopenia as a potential predictor of ipsilateral breast tumor recurrence in early breast cancer. Anticancer Research. 2019; 39: 4467–4474.

[24] Yu XF, Yang HJ, Yu Y, Zou DH, Miao LL. A prognostic analysis of male breast cancer (MBC) compared with post-menopausal female breast cancer (FBC). PLOS ONE. 2015; 10: e0136670.

[25] Zhao FY, Liu JE, Fang XM, Chen L, Liang JG, Liu Y, et al. Effects of a 12-week exercise-based intervention on weight management in overweight or obese breast cancer survivors: a randomized controlled trial. Supportive Care in Cancer. 2024; 32: 98.

[26] Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Male breast cancer. Critical Reviews in Oncology/Hematology. 2010; 73: 141–155.

[27] Koleilat I, Syal A, Hena M. Metastatic male ductal breast cancer mimicking obstructing primary colon cancer. International Journal of Biomedical Science. 2010; 6: 66–70.

[28] Ko JH, Kim JH, Ham DH. Surgical treatment of male breast cancer metastasis to thoracic spine: a case report. Medicine. 2023; 102: e36252.

[29] Mada SR, Zay HH, Bies JJ, Massebo E, Didia C. A rare case of remittent male invasive ductal carcinoma with new metastasis after incomplete adjuvant therapy. Cureus. 2023; 15: e50400.

[30] Jones SE. Metastatic breast cancer: the treatment challenge. Clinical Breast Cancer. 2008; 8: 224–233.

[31] Dragoumis DM, Assimaki AS, Tsiftsoglou AP. Pure mucinous carcinoma with axillary lymph node metastasis in a male breast. Breast Cancer. 2012; 19: 365–368.

[32] Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clinical Cancer Research. 2011; 17: 4834–4843.

[33] de Almeida Freire N, de Andrade BAB, Silva Canedo NH, Agostini M, Romañach MJ. Oral and maxillofacial metastasis of male breast cancer: report of a rare case and literature review. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology. 2019; 127: e18–e22.

[34] Fentiman IS. The endocrinology of male breast cancer. Endocrine-Related Cancer. 2018; 25: R365–R373.

[35] Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Current Oncology. 2010; 17: 17–21.

[36] Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Annals of Oncology. 2012; 23: 1471–1474.

[37] Masci G, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist. 2015; 20: 586–592.

[38] Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, et al. Management of male breast cancer: ASCO guideline. Journal of Clinical Oncology. 2020; 38: 1849–1863.

[39] Wu M, Wang J, Zhou W, Wang M, Hu C, Zhou M, et al. Vitamin D inhibits tamoxifen-induced non-alcoholic fatty liver disease through a nonclassical estrogen receptor/liver X receptor pathway. Chemico-Biological Interactions. 2024; 389: 110865.

[40] Hackshaw-McGeagh LE, Penfold CM, Walsh E, Donovan JL, Hamdy FC, Neal DE, et al.; ProtecT Study Group. Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification. International Journal of Cancer. 2015; 137: 1509–1515.

[41] Nonomiya Y, Nakayama I, Kobayashi K, Amakawa Y, Shibata N, Soejima A, et al. Analysis of adverse events associated with trastuzumab deruxtecan in patients with gastric and breast cancer: a retrospective study. Biological and Pharmaceutical Bulletin. 2024; 47: 411–416.

[42] Liang Y, Zhang P, Li F, Lai H, Qi T, Wang Y. Advances in the study of marketed antibody-drug conjugates (ADCs) for the treatment of breast cancer. Frontiers in Pharmacology. 2024; 14: 1332539.

[43] Chichura A, Attai DJ, Kuchta K, Nicholson K, Kopkash K, Pesce C, et al. Male breast cancer patient and surgeon experience: the male WhySurg study. Annals of Surgical Oncology. 2022; 29: 6115–6131.

[44] Edman Kessler L, Sigfridsson J, Hatzidaki D, Bergh J, Foukakis T, Georgoulias V, et al. Chemotherapy use near the end-of-life in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 2020; 181: 645–651.

[45] Wang F, Shu X, Meszoely I, Pal T, Mayer IA, Yu Z, et al. Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncology. 2019; 5: 1589–1596.

[46] Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Research and Treatment. 2013; 137: 465–470.

[47] Towfighi P, Haffner ZK, Sayyed AA, Deldar R, Sogunro O, Hawa AAAE, et al. Breast reconstruction in male breast cancer patients: an analysis of trends using the NSQIP database. European Journal of Plastic Surgery. 2023; 46: 1113–1119.

[48] Reinisch M, Seiler S, Hauzenberger T, Kamischke A, Schmatloch S, Strittmatter HJ, et al. Efficacy of endocrine therapy for the treatment of breast cancer in men: results from the MALE phase 2 randomized clinical trial. JAMA Oncology. 2021; 7: 565–572.

[49] Valentini V, Bucalo A, Conti G, Celli L, Porzio V, Capalbo C, et al. Gender-specific genetic predisposition to breast cancer: BRCA genes and beyond. Cancers. 2024; 16: 579.

[50] Arzanova E, Mayrovitz HN. Male breast cancer: treatment trends, reported outcomes, and suggested recommendations. Cureus. 2021; 13: e18337.

[51] Chang O, Choi EK, Kim IR, Nam SJ, Lee JE, Lee SK, et al. Association between socioeconomic status and altered appearance distress, body image, and quality of life among breast cancer patients. Asian Pacific Journal of Cancer Prevention. 2014; 15: 8607–8612.

[52] Stor MLE, Lokhorst MM, Horbach SER, Young-Afat DA, Spuls PI, van der Horst CMAM. Appearance-related concerns and their impact on health-related quality of life in patients with peripheral vascular malformations. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2022; 75: 4202–4211.

[53] Lee J, Lee KS, Sim SH, Chae H, Sohn J, Kim GM, et al. Impacts of subtype on clinical feature and outcome of male breast cancer: multicenter study in Korea (KCSG BR16-09). Cancer Research and Treatment. 2023; 55: 123–135.

[54] Gao X, Caruso BR, Li W. Advanced hydrogels in breast cancer therapy. Gels. 2024; 10: 479.

[55] Fentiman IS. Risk factors for male breast cancer. American Journal of Translational Research. 2023; 15: 6918–6925.

[56] Bodai BI, Tuso P. Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. The Permanente Journal. 2015; 19: 48–79.

[57] Kovačević I, Pavić J, Filipović B, Ozimec Vulinec Š, Ilić B, Petek D. Integrated approach to chronic pain-the role of psychosocial factors and multidisciplinary treatment: a narrative review. International Journal of Environmental Research and Public Health. 2024; 21: 1135.

[58] Weingarden H, Wilhelm S, Jacobs JM, Carrellas J, Cetrulo C, Austen WG III, et al. Prospective examination of psychological risk and maintenance factors for body image distress after mastectomy with immediate breast reconstruction. Body Image. 2022; 42: 120–125.

[59] Avila J, Herrick B, Attai DJ, Leone JP. Treatments for breast cancer in men: late effects and impact on quality of life. Breast Cancer Research and Treatment. 2023; 201: 489–498.

[60] Giordano SH. Breast cancer in men. The New England Journal of Medicine. 2018; 378: 2311–2320.

[61] McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, et al. Analysis of the clinical advancements for BRCA-related malignancies highlights the lack of treatment evidence for BRCA-positive male breast cancer. Cancers. 2022; 14: 3175.

[62] Rosso R, D'Alonzo M, Bounous VE, Actis S, Cipullo I, Salerno E, et al. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. Current Oncology. 2023; 30: 1461–1472.

[63] Sun X, Liu K, Lu S, He W, Du Z. Targeted therapy and immunotherapy for heterogeneous breast cancer. Cancers. 2022; 14: 5456.

[64] Wu Z, Wang J, You F, Li X, Xiao C. The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-positive metastatic breast cancer. Frontiers in Pharmacology. 2023; 14: 1142087.

[65] Jayaraman S, Reid JM, Hawse JR, Goetz MP. Endoxifen, an estrogen receptor targeted therapy: from bench to bedside. Endocrinology. 2021; 162: bqab191.

[66] Varzaru VB, Anastasiu-Popov D-M, Eftenoiu A-E, Popescu R, Vlad DC, Vlad CS, et al. Observational study of men and women with breast cancer in terms of overall survival. Cancers. 2024; 16: 3049.

[67] Bootsma TI, Duijveman P, Pijpe A, Scheelings PC, Witkamp AJ, Bleiker EMA. Unmet information needs of men with breast cancer and health professionals. Psycho-Oncology. 2020; 29: 851–860.

[68] Sabih QA, Young J, Takabe K. Management of male breast cancer: the journey so far and future directions. World Journal of Clinical Oncology. 2021; 12: 206–213.

[69] Cox K, Alford B, Soliman H. Emerging therapeutic strategies in breast cancer. Southern Medical Journal. 2017; 110: 632–637.